Journal Article

Activity of human β-defensins 2 and 3 against ESBL-producing <i>Klebsiella</i> strains

Hany Sahly, Sabine Schubert, Jürgen Harder, Michael Kleine, Dorthe Sandvang, Uwe Ullmann, Jens M. Schröder and Rainer Podschun

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 57, issue 3, pages 562-565
Published in print March 2006 | ISSN: 0305-7453
Published online January 2006 | e-ISSN: 1460-2091 | DOI:
Activity of human β-defensins 2 and 3 against ESBL-producing Klebsiella strains

More Like This

Show all results sharing these subjects:

  • Medical Oncology
  • Critical Care


Show Summary Details


Objectives: To test the bactericidal activity of human β-defensins (hBDs) 2 and 3 against extended-spectrum β-lactamase (ESBL)-producing Klebsiella strains.

Methods: Thirty-six Klebsiella pneumoniae and seventeen Klebsiella oxytoca ESBL-producing isolates from nosocomial infections were tested. The bactericidal activity of recombinantly synthesized hBD-2 and -3 was tested and the results were given either as lethal doses killing ≥90% of bacteria (LD90s) or as MBCs (≥99.9% killing).

Results: Except for one intermediately susceptible strain (MBC = 25 mg/L), all other ESBL-producing strains were highly susceptible to both defensins (LD90s and MBCs ≤ 12.5mg/L).

Conclusions: The results underline the high efficacy of hBD-2 and -3 against ESBL-producing Klebsiella, making both defensins attractive candidates as antimicrobial agents to combat these increasingly troublesome bacteria.

Keywords: multidrug resistance; innate immunity; Klebsiella spp

Journal Article.  1791 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.